Dufalak (lactulose) syrup 667 mg/1 ml. sackets 15 ml. №10

Description

Dufalak syrup Composition
active substance: lactulose;

1 ml of syrup contains 667 mg of lactulose;

Dufalak syrup excipient: purified water.

Dufalak syrup Dosage form
Syrup.

Basic physical and chemical properties: transparent thick liquid from colorless to brownish-yellow.

Pharmacological group
Osmotic laxatives. ATX code A06A D11.

Pharmacological properties

Pharmacodynamics.

In the colon, lactulose is broken down by intestinal bacteria to low molecular weight organic acids. These acids lower the pH in the lumen of the colon and, due to the osmotic effect, increase the volume of intestinal contents. This stimulates the peristalsis of the large intestine and normalizes the consistency of feces. Constipation is corrected and the physiological rhythm of the intestine is restored.

In hepatic encephalopathy (or hepatic coma and precoma), the effect of the drug is due to inhibition of the growth of proteolytic bacteria due to an increase in the number of acidophilic bacteria (for example lactobacilli), binding of ammonia in ionic form due to acidification of intestinal contents, cleansing of the large intestine due to low pH, as well as the osmotic effect , by changing bacterial nitrogen metabolism by stimulating the utilization of ammonia by bacteria for the synthesis of bacterial proteins. In the context of the above, it should be noted, however, that the neuropsychiatric manifestations of hepatic encephalopathy cannot be explained by hyperammonemia alone. However, ammonia can be considered as a sample of other nitrogen compounds.

Lactulose as a prebiotic enhances the growth of beneficial bacteria such as bifidobacteria and lactobacilli, while the growth of potentially pathogenic bacteria such as clostridium and E. coli can be suppressed. This can lead to a more favorable balance of the intestinal flora.

Pharmacokinetics.

Lactulose is almost not absorbed after oral administration and reaches the large intestine unchanged, where it is metabolized by the bacterial flora. When using Dufalaka® at a dose of 25-50 g or 40-75 ml, lactulose is completely metabolized. When using higher doses, part of the lactulose may be excreted unchanged.

Indications
Constipation: regulation of the physiological rhythm of the intestinal tract.
Conditions requiring relief of bowel movements (hemorrhoids after operations on the large intestine and anorectal zone).
Hepatic encephalopathy: treatment and prevention of hepatic coma and precoma.

Contraindications
Hypersensitivity to the active substance or other components of the drug, galactosemia, gastrointestinal obstruction, perforation of the digestive tract or the risk of perforation of the digestive tract.